CFM
BTAI icon

Catalyst Funds Management’s BioXcel Therapeutics BTAI Stock Holding History

Catalyst Funds Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-325
Closed -$3.17K – 455
2024
Q3 		$3.17K Hold
325
– – ﹤0.01% 1259
2024
Q2 		$6.66K Buy
+325
New +$10.9K ﹤0.01% 1008

Other funds holding BTAI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Catalyst Funds Management's BTAI Position: Q4 2024 in Review

Catalyst Funds Management sold out of BioXcel Therapeutics (BTAI) in Q4 2024, closing a stake of 325 shares — an estimated $3.17K sold.

Catalyst Funds Management first reported a position in BTAI in Q2 2024 and held it in 2 quarters. The position peaked at $6.66K in Q2 2024. 49 funds tracked by Wall St. Rank hold BTAI as of Q4 2024.

  • Catalyst Funds Management reported no remaining BioXcel Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 325 BioXcel Therapeutics shares in Q4 2024, an estimated $3.17K.
  • Catalyst Funds Management first reported a position in BioXcel Therapeutics in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's BioXcel Therapeutics position peaked at $6.66K in Q2 2024.
  • 49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.